Osage University Partners

Osage University Partners

Type	Private ownership
Industry	Venture Capital
Founded	2011
Headquarters	Philadelphia, Pennsylvania, United States
Website	www.osageuniversitypartners.com

Osage University Partners (OUP) is a venture capital fund specializing in university spinouts. OUP has partnerships with 80+ affiliated universities, national labs, and research institutions. The fund invests in all stages of development including seed, early, and late stage. General partners include Robert Adelson, Bill Harrington,^[1] Marc Singer, and founding partner Louis Berneman. OUP is part of Osage Partners,^[2] a family of investment funds with diversified investment strategies including Osage Venture Partners.^[3]

Investment Strategy

Osage University Partners invests across all sectors of university commercialization, including Information Technology, Energy, Materials, and Life Science. The fund invests across all stages, including seed, early, and late. OUP closed its first fund in 2011, a $100 million fund from diverse institutional investors.^[4] The fund promotes the venture and entrepreneurship ecosystems around universities, typically co-investing with other leading venture capital firms.

Participation Rights

Through their licensing activities, universities and research institutions generally have the right (a “Participation Right”) to invest in their own spin-outs. Historically, few universities or research institutions have exercised such rights. OUP utilizes these rights to invest in university spinouts, and in return universities and research institutions share in the fund’s profits.^[5]

OUP seeks to make investments by primarily exercising the Participation Rights of its partner universities, and if no formal Participation Right exists, to participate as a co-investor on behalf of the university or research institution.^[6]

Affiliated institutions

Albert Einstein College of Medicine
Arizona State University
Ben Gurion University of the Negev
Brigham Young University
Brown University
Caltech
Carnegie Mellon
The Children's Hospital of Philadelphia
Cold Spring Harbor Laboratory
Columbia University
Cornell University
Dana-Farber Cancer Center
Drexel University
Duke University
Emory University
Fred Hutchinson Cancer Center
Georgia Tech
Harvard University
The Hebrew University of Jerusalem
International Computer Science Institute
Johns Hopkins University
Lawrence Berkeley National Lab
Lawrence Livermore National Laboratory
MaRS Innovation
NC State
MD Anderson Cancer Center
Michigan State University
Mount Sinai
National University of Singapore
New York University
NC State University
Northwestern University
Oklahoma Medical Research Foundation
Oregon Health & Science University
PARC
Penn State University
Princeton University
Rice University
Rockefeller University
Rutgers University
Salk Institute for Biological Studies
Sanford Burnham
Tel Aviv University
Temple University
The Scripps Research Institute
Tufts University
Tulane University
UC Berkeley
UC Davis
UC Irvine
UC Los Angeles
UC San Diego
UC San Francisco
UC Santa Barbara
University of Chicago
University of Colorado
University of Delaware
University of Florida
University of Illinois
University of Iowa
University of Maryland
University of Michigan
University of Minnesota
University of New Mexico
University of North Carolina
University of Notre Dame
University of Pennsylvania
University of Pittsburgh
University of South Florida
University of Southern California
University of Texas System
University of Toronto
University of Utah
University of Virginia
University of Washington
University of Waterloo
Utah State University
Virginia Tech
Yeda (Weizmann Institute of Science)

Portfolio Companies

Portfolio companies include, Aerie Pharmaceuticals, AGTC, Algorithmia, Ambiq Micro, Aptinyx, Atterocor, Avid Radiopharmaceuticals, Blade Therapeutics, Body Labs, Cancer Guide, Capella Bioscience, Cardioxyl, Cell Design Labs, Clarifai, Cleave Biosciences, Clinipace Worldwide, Corridor Pharmaceuticals, eFFECTOR Therapeutics, Enlibrium, Evolv Technologies, Faraday, Gevo (NASDAQ: GEVO), Guardant Health, Iconic Therapeutics, Immune Design, Infinio, Jibo, Kolltan Pharmaceuticals, Kura Oncology, Kymeta,^[7] Liquid Light, Luxtera, Menlo Security, Merganser Biotech, MC10, Millendo Therapeutics, Mirna Therapeutics, Otonomy,^[8] Paracosm, Picwell, PMV Pharma, Psikick, Precision Biosciences, Receptos (NASDAQ: RCPT), Ribon Therapeutics, Seismos Technologies, Selecta Biosciences, Sera Prognostics, Skytree, Spero Therapeutics, SolarBridge Technologies, Streetlight Data, Tangent Medical, Urjanet, Virdante Pharmaceuticals, and Voxel8

References

↑ "William Harrington Joins Osage University Partners as Managing Partner". Yahoo Finance. Jan 5, 2012.
↑ "Osage Partners". Osage Partners.
↑ "Osage Venture Partners". Osage Venture Partners.
↑ "It Came From Their Lab. But How to Take It to the Bank?". NY Times. March 12, 2011.
↑ "Osage University Partners Expanding Its Novel Venture Firm Model". Xconomy. Retrieved February 28, 2013.
↑ "Investment Criteria". Osage University Partners.
↑ http://online.wsj.com/article/PR-CO-20130709-904182.html?mod=googlenews_wsj
↑ http://www.fiercebiotech.com/story/otonomy-banks-46m-pivotal-studies-treat-ear-conditions/2013-09-04

External links

Private equity and venture capital investment firms

Investment strategy	Venture Growth Mezzanine Secondaries Leveraged buyout

History	History of private equity and venture capital Early history of private equity Private equity in the 1980s Private equity in the 1990s Private equity in the 2000s

Investors	Angel investor Corporate venture capital Commercial bank Crowdfunding Institutional investor Insurance company Investment bank Endowment Family office Fund of funds High-net-worth individual Merchant bank Pension fund Sovereign wealth fund

Private equity firms Venture capital firms Portfolio companies

This article is issued from Wikipedia - version of the 11/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.